706-3SBio

N/A

Report date: 2025/08/29 20:01:31

Base Information

Drug Name706-3SBio
Drug Alias NameSSGJ-706706 anti -PD1/PD -L1 BsAb706 anti-PD1/PD-L1 Bispecific antibody
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-PD-1Anti-Programmed death-ligand 1
TargetsProgrammed cell death protein 1Programmed death-ligand 1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator Companies3sbio Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShenyang Sunshine Pharmaceutical Co LtdSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[8] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A